Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids
Brief Summary: Primary Objective:

To evaluate the efficacy of dupilumab 300 milligram (mg) every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyp score (NPS) in participants with bilateral nasal polyposis (NP). In addition for Japan participants, reduction in computed tomography (CT) scan opacification of the sinuses was a coprimary objective.

Secondary Objectives:

* To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).
* To evaluate the efficacy of dupilumab in improving sense of smell.
* To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (primary objective for Japan).
* To evaluate ability of dupilumab in reducing proportion of participants requiring treatment with systemic corticosteroids or NP surgery.
* To evaluate the effect of dupilumab on participant reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).
* To evaluate the effect of dupilumab in the subgroups of participants with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug \[NSAID\] exacerbated respiratory disease \[ERD\]).
* To evaluate residual effect in follow up.
* To evaluate the safety of dupilumab in participants with bilateral NP.
* To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatment-emergent anti-drug antibodies.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Mometasone furoate 50 micrograms | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab SAR231893 (REGN668), Drug: Mometasone furoate 50 micrograms | Intervention Type: DRUG; Name: Dupilumab SAR231893 (REGN668); Assigned to Arm(s): Dupilumab 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mometasone furoate 50 micrograms; Assigned to Arm(s): Dupilumab 300 mg, Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Intervention Type: DRUG; Name: Anti-IgE antibody omalizumab or placebo; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Placebo q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Dupilumab 200 mg q4w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: ICS/LABA therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Levosalbutamol/levalbuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w

Answer: A